FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010169076> ?p ?o ?g. }

• W2010169076 endingPage "203" @default.
• W2010169076 startingPage "192" @default.
• W2010169076 abstract "Abstract Background Psoriasis is a chronic, inflammatory skin disease with a significant impact on health–related quality of life ( HRQ oL). Tofacitinib ( CP ‐690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator. Objective This Phase 2b study assessed three tofacitinib dosage regimens vs. placebo to characterize the efficacy and safety of tofacitinib in patients with moderate–to‐severe chronic plaque psoriasis. We report the patient‐reported outcome ( PRO ) data. Methods A total of 197 patients were randomized to tofacitinib 2, 5, 15 mg twice daily or placebo for 12 weeks. Six PRO questionnaires were completed during the study: Dermatology Life Quality Index, Itch Severity Score ( ISS ), Short Form‐36 questionnaire, version 2 ( SF ‐36), Pain/Discomfort Assessment ( PDA ), Patient Satisfaction with Study Medication ( PSSM ) item and Patient Global Assessment of psoriasis. Results Treatment with tofacitinib resulted in significant, dose‐dependent improvements in several PRO s vs. placebo from week 2 onwards. At week 12, least squares mean changes from baseline for Dermatology life quality index, ISS and SF ‐36 mental component scores were significantly greater for all active drug arms vs. placebo ( P < 0.05), and significantly greater for tofacitinib 5 and 15 mg for SF ‐36 physical component scores vs. placebo ( P < 0.05). At week 12, all dose groups had significantly greater numbers of patients reporting ‘Clear’ or ‘Almost clear’ on the Pt GA vs. placebo. Conclusion In patients with moderate–to–severe chronic plaque psoriasis, short‐term (12–week) treatment with oral twice‐daily tofacitinib improves HRQ oL outcomes and patient assessment of disease severity and symptoms, with an early onset noted." @default.
• W2010169076 created "2016-06-24" @default.
• W2010169076 creator A5043906653 @default.
• W2010169076 creator A5059435575 @default.
• W2010169076 creator A5075798284 @default.
• W2010169076 creator A5090399884 @default.
• W2010169076 date "2013-01-07" @default.
• W2010169076 modified "2023-10-03" @default.
• W2010169076 title "Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis" @default.
• W2010169076 cites W1550341007 @default.
• W2010169076 cites W1990127867 @default.
• W2010169076 cites W2030298480 @default.
• W2010169076 cites W2031157372 @default.
• W2010169076 cites W2031611115 @default.
• W2010169076 cites W2036607940 @default.
• W2010169076 cites W2048964610 @default.
• W2010169076 cites W2061785558 @default.
• W2010169076 cites W2068795846 @default.
• W2010169076 cites W2074439189 @default.
• W2010169076 cites W2075934703 @default.
• W2010169076 cites W2080165152 @default.
• W2010169076 cites W2088804269 @default.
• W2010169076 cites W2095297002 @default.
• W2010169076 cites W2096445837 @default.
• W2010169076 cites W2097007448 @default.
• W2010169076 cites W2098119609 @default.
• W2010169076 cites W2101217991 @default.
• W2010169076 cites W2107479848 @default.
• W2010169076 cites W2113295791 @default.
• W2010169076 cites W2121588356 @default.
• W2010169076 cites W2161895264 @default.
• W2010169076 cites W2165657093 @default.
• W2010169076 cites W2167305078 @default.
• W2010169076 cites W2168751090 @default.
• W2010169076 cites W2742484040 @default.
• W2010169076 doi "https://doi.org/10.1111/jdv.12081" @default.
• W2010169076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23294276" @default.
• W2010169076 hasPublicationYear "2013" @default.
• W2010169076 type Work @default.
• W2010169076 sameAs 2010169076 @default.
• W2010169076 citedByCount "57" @default.
• W2010169076 countsByYear W20101690762013 @default.
• W2010169076 countsByYear W20101690762014 @default.
• W2010169076 countsByYear W20101690762015 @default.
• W2010169076 countsByYear W20101690762016 @default.
• W2010169076 countsByYear W20101690762017 @default.
• W2010169076 countsByYear W20101690762018 @default.
• W2010169076 countsByYear W20101690762019 @default.
• W2010169076 countsByYear W20101690762020 @default.
• W2010169076 countsByYear W20101690762021 @default.
• W2010169076 countsByYear W20101690762022 @default.
• W2010169076 countsByYear W20101690762023 @default.
• W2010169076 crossrefType "journal-article" @default.
• W2010169076 hasAuthorship W2010169076A5043906653 @default.
• W2010169076 hasAuthorship W2010169076A5059435575 @default.
• W2010169076 hasAuthorship W2010169076A5075798284 @default.
• W2010169076 hasAuthorship W2010169076A5090399884 @default.
• W2010169076 hasConcept C126322002 @default.
• W2010169076 hasConcept C142724271 @default.
• W2010169076 hasConcept C159110408 @default.
• W2010169076 hasConcept C16005928 @default.
• W2010169076 hasConcept C168563851 @default.
• W2010169076 hasConcept C197934379 @default.
• W2010169076 hasConcept C204787440 @default.
• W2010169076 hasConcept C27081682 @default.
• W2010169076 hasConcept C2776173921 @default.
• W2010169076 hasConcept C2776233030 @default.
• W2010169076 hasConcept C2777011040 @default.
• W2010169076 hasConcept C2777575956 @default.
• W2010169076 hasConcept C2778886723 @default.
• W2010169076 hasConcept C2779951463 @default.
• W2010169076 hasConcept C2780564577 @default.
• W2010169076 hasConcept C71924100 @default.
• W2010169076 hasConcept C90924648 @default.
• W2010169076 hasConceptScore W2010169076C126322002 @default.
• W2010169076 hasConceptScore W2010169076C142724271 @default.
• W2010169076 hasConceptScore W2010169076C159110408 @default.
• W2010169076 hasConceptScore W2010169076C16005928 @default.
• W2010169076 hasConceptScore W2010169076C168563851 @default.
• W2010169076 hasConceptScore W2010169076C197934379 @default.
• W2010169076 hasConceptScore W2010169076C204787440 @default.
• W2010169076 hasConceptScore W2010169076C27081682 @default.
• W2010169076 hasConceptScore W2010169076C2776173921 @default.
• W2010169076 hasConceptScore W2010169076C2776233030 @default.
• W2010169076 hasConceptScore W2010169076C2777011040 @default.
• W2010169076 hasConceptScore W2010169076C2777575956 @default.
• W2010169076 hasConceptScore W2010169076C2778886723 @default.
• W2010169076 hasConceptScore W2010169076C2779951463 @default.
• W2010169076 hasConceptScore W2010169076C2780564577 @default.
• W2010169076 hasConceptScore W2010169076C71924100 @default.
• W2010169076 hasConceptScore W2010169076C90924648 @default.
• W2010169076 hasIssue "2" @default.
• W2010169076 hasLocation W20101690761 @default.
• W2010169076 hasLocation W20101690762 @default.
• W2010169076 hasOpenAccess W2010169076 @default.
• W2010169076 hasPrimaryLocation W20101690761 @default.
• W2010169076 hasRelatedWork W1541270304 @default.
• W2010169076 hasRelatedWork W1978428707 @default.

• next